AstraZeneca says the Department of Justice is ending its investigation into PLATO, a clinical trial with its heart drug Brilinta, and is not planning any further action. It began investigating the PLATO trial, which studied more than 18,000 patients in 43 countries, last October after suspicions were raised that the clinical trial numbers may have been manipulated. In a statement, AstraZeneca CEO Pascal Soriot said, "We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit Brilinta offers to patients around the world suffering from acute coronary syndrome."

If you liked this article you might like

IPOs That Should Be on Your Radar

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting